From: Biases affecting injected doses of an experimental drug during clinical trials
Dose level [MIU] | TW i | W i | Median relative bias | Route | |
---|---|---|---|---|---|
[mg] | [mg] | Bias [%] | Range | ||
0.5 | 41.6 | 20.8 | −73.6 % | 205.1 % | Intravenous |
1.0 | 83.2 | 50.5 | −51.0 % | 119.8 % | Intravenous |
1.5 | 124.8 | 106.5 | −15.1 % | 30.3 % | Subcutaneous |
2.0 | 166.4 | 154.3 | −8.1 % | 23.9 % | Intravenous |
3.0 | 249.6 | 239.7 | −5.4 % | 9.7 % | Subcutaneous |
4.0 | 332.8 | 326.2 | −1.3 % | 11.8 % | Intravenous |
6.0 | 499.2 | 529.1 | 6.1 % | 4.0 % | Subcutaneous |